Ultragenyx Pharmaceutical Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Ultragenyx is a rare-disease biopharmaceutical company with four approved products and a clinical-stage pipeline. The filing was signed May 2, 2024; financial figures below are in U.S. dollars unless indicated otherwise.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Total revenue | $108.8 million | $100.5 million | Up 8% |
| Product sales | $62.5 million | $44.2 million | Up 41% |
| Operating expenses | $274.2 million | $254.6 million | Up 8% |
| Operating loss | $(165.3) million | $(154.1) million | Loss widened |
| Net loss | $(170.7) million | $(164.0) million | Loss widened about 4% |
| Net loss per share, diluted | $(2.03) | $(2.33) | Less loss per share; weighted-average shares increased |
| Cash used in operating activities | $(190.7) million | $(156.9) million | Higher operating cash use |
Product sales were led by Crysvita ($36.2 million), Dojolvi ($16.4 million), Mepsevii ($6.6 million) and Evkeeza ($3.3 million). The filing does not separately present gross profit or gross margin.
At March 31, 2024, cash and cash equivalents were $112.3 million and marketable debt securities totaled $456.4 million, or $568.7 million combined. Total assets were $1.307 billion; stockholders’ equity was $140.3 million. The company reported $891.4 million of liabilities for sales of future royalties, including $42.7 million current. The filing does not report conventional borrowings as a balance-sheet line item; lease liabilities totaled $40.8 million.
Cash, cash equivalents and restricted cash declined by $97.0 million during the quarter. Investing activities provided $94.4 million, principally from net maturities and sales of marketable securities; this was not operating cash generation. Management said existing capital resources should fund projected operating requirements for at least 12 months.
Material changes versus Q1 2023
- Crysvita product sales rose 71% to $36.2 million, while total product sales grew 41%, supported by demand, particularly in Latin America, and growth in other approved products and named-patient programs.
- Crysvita royalty revenue was $46.3 million versus $4.9 million. Conversely, collaboration and license revenue fell to zero from $51.4 million. This primarily reflects the April 2023 transition of U.S. and Canada commercialization responsibilities to Kyowa Kirin (KKC) and the change from profit-share collaboration revenue to royalty revenue; the categories are not directly comparable.
- Mepsevii sales declined 22% to $6.6 million. Dojolvi sales increased 14% to $16.4 million; Evkeeza sales were $3.3 million versus $0.2 million.
- Research and development expense increased 8% to $178.5 million, including higher gene-therapy and biologic/nucleic-acid program spending. Selling, general and administrative expense increased 2% to $78.2 million.
- Operating cash use increased by $33.9 million, reflecting the larger operating loss and working-capital use, including higher receivables and timing of payments.
Outlook, developments and risks
- Management expects annual losses to continue for the foreseeable future and says future capital needs depend on clinical progress, manufacturing, commercialization and other factors. It may seek funding through equity, debt, collaborations, licensing or royalty transactions. A $350 million at-the-market equity program was authorized in February 2024; no shares had been sold under it by March 31.
- Management expects 2024 North American Crysvita tiered royalty revenue to average at the upper end of the applicable range. It expects R&D and SG&A expenses to moderate in the near term, though R&D timing and costs remain dependent on study outcomes and regulatory requirements. No numerical full-year revenue or earnings guidance is provided in the filing text.
- Pipeline milestones cited include DTX401 Phase 3 results expected in Q2 2024; DTX301 Phase 3 enrollment expected to complete in the second half of 2024; and UX701 Stage 1 data expected in the second half of 2024. In April 2024, the company reported enrollment completion in the Phase 3 Orbit and Cosmic studies of setrusumab and presented interim GTX-102 data; it expected FDA End-of-Phase-2 discussions in mid-2024. These are forward-looking expectations, not reported outcomes.
- GTX-102 interim findings included two reports of mild or moderate lower-extremity weakness among 53 patients who completed the Expansion Cohorts’ loading phase as of April 5, 2024; the weakness resolved rapidly without sequelae. The company reported no other unexpected serious adverse events and said regulators raised no issues or required additional action.
- Key risks include continued operating losses and potential need for additional capital; uncertain clinical and regulatory outcomes; gene-therapy manufacturing, supply and facility execution; dependence on KKC for Crysvita supply and commercialization in important territories; pricing, reimbursement and patient identification; and competition and intellectual-property challenges. The company also disclosed prior cybersecurity incidents involving third-party unauthorized access to and misappropriation of financial information and clinical data.
- Future royalty-sale liabilities are sensitive to Crysvita sales and royalty timing; changes in estimates can affect non-cash interest expense. The company reported no material legal proceedings and said disclosure controls were effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether continued product demand—especially Crysvita and Latin American sales—supports revenue growth, and how the post-transition royalty revenue compares economically with prior profit-share revenue.
- Actual clinical readouts and regulatory progress for DTX401, DTX301, UX701, GTX-102 and setrusumab against the company’s stated timelines.
- Operating cash burn, receivable collections and the sufficiency of the stated liquidity runway, including any use of the $350 million ATM facility or other financing.
- Terms, estimated repayment trajectory and sensitivity of the $891.4 million future-royalty liabilities, alongside milestone, royalty, lease and manufacturing commitments.
- Supply continuity, including qualification of an alternative Dojolvi drug-product supplier following closure of the prior supplier’s site, and the company’s reliance on single-source suppliers.
- Potential dilution from equity compensation, pre-funded warrants and future share sales. The company reported 83,133,341 common shares outstanding as of April 26, 2024.